Article Type
Editorial
Published
This editorial describes the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
Editorial
This editorial describes the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
Review
Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.